Kymera Therapeutics KYMR Free cash flow yield
Free cash flow yield at other companies
Other financials
Where this comes from
Calculated from Kymera Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's free cash flow yield.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's free cash flow yield?
- Kymera Therapeutics (KYMR) reported free cash flow yield of -3.6% in Q1 2026.
- How has Kymera Therapeutics's free cash flow yield changed year-over-year?
- Kymera Therapeutics's free cash flow yield increased by 73.4% year-over-year, from -13.5% to -3.6%.
- What is the long-term trend for Kymera Therapeutics's free cash flow yield?
- Over 4 years (2021 to 2025), Kymera Therapeutics's free cash flow yield has grown at a -1.4% compound annual growth rate (CAGR), from -4% to -3.8%.
- What does free cash flow yield mean?
- Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.